Technophage honored with a Healthcare & Pharmaceutical Award

Technophage honored with a Healthcare & Pharmaceutical Award

For eight years in a row, the Healthcare & Pharmaceutical Awards have recognized the pioneers transforming our healthcare field. We are thrilled to announce that Technophage has been recognized as the “Most Innovative Biopharmaceutical Company 2023 –...
TZ-161 one step closer to clinical trials in spinal cord injury

TZ-161 one step closer to clinical trials in spinal cord injury

Technophage is thrilled to share that TZ-161 product is now one step closer to potentially becoming a pioneering repurposed treatment for patients suffering from acute spinal cord injury. This innovative product, currently undergoing clinical trial application in...
TP-102 clinical trial presented at ECCMID 2023

TP-102 clinical trial presented at ECCMID 2023

Last month Technophage team attended 33rd European Congress of Clinical Microbiology & Infectious Diseases with the clinical team from Israel, and Dr. Ran Nir-Paz from Hadassah Medical Center, presented the results obtained in the Phase I/IIa double-blinded,...
Technophage featured in ‘The Economist’

Technophage featured in ‘The Economist’

Technophage has been featured in ‘The Economist’ journal. The piece entitled ‘Western firms are becoming interested in a Soviet medicine’ describes how phage therapy is helping patients around the globe, highlighting the increased interest of western...